Is Apyx Medical Corp well-positioned for April economic uncertainties?

As many millenniums are excited about healthcare space, it is only fair to break down Apyx Medical Corp. We will check why this entity may not get much respect from investors given the current market uncertainty. Is Apyx Medical Corp current valuation justified for 2022? Here i will cover my perspective on valuation to give Apyx Medical investors a better outlook on taking a position in the stock.
Published over a year ago
View all stories for Apyx Medical | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

This firm currently holds 395 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the firm is not taking enough advantage from borrowing. The company has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Apyx Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Apyx Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Apyx Medical Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Apyx Medical to invest in growth at high rates of return. When we think about Apyx Medical's use of debt, we should always consider it together with cash and equity.Apyx Medical is UNDERVALUED at 9.55 per share with modest projections ahead.
We determine the current worth of Apyx Medical using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Apyx Medical based exclusively on its fundamental and basic technical indicators. By analyzing Apyx Medical's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Apyx Medical's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apyx Medical. We calculate exposure to Apyx Medical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Apyx Medical's related companies.

Watch out for price decline

Please consider monitoring Apyx Medical on a daily basis if you are holding a position in it. Apyx Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Apyx Medical stock to be traded above the $1 level to remain listed. If Apyx Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Apyx Medical Investment Alerts

Apyx investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Apyx Medical performance across your portfolios.Please check all investment alerts for Apyx

Apyx Medical Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Apyx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apyx Medical competition to find correlations between indicators driving the intrinsic value of Apyx.

Details

The big decline in price over the last few months for Apyx Medical Corp could raise concerns from investors as the firm is trading at a share price of 6.94 on 331,735 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in February. However, diversifying your holdings with Apyx Medical Corp or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.94. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Apyx Medical partners.
 2019 2020 2021 2022 (projected)
Interest Expense8 K46 K41.4 K42.49 K
Gross Profit19.09 M17.5 M20.13 M17.1 M

Margins Breakdown

Apyx Medical profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Apyx Medical itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Apyx Medical profit margins.
EBITDA Margin(0.79)
Gross Margin0.68
Profit Margin(0.51)
Apyx Medical Average Equity is increasing over the last 8 years. Also, Apyx Medical Earnings before Tax is decreasing over the last 8 years. The current value of Apyx Medical Earnings before Tax is -22,895,925.

Our perspective of the current Apyx Medical rise

Apyx Medical current standard deviation rises over 6.32.
As of the 16th of March 2022, Apyx Medical shows the risk adjusted performance of (0.16), and Mean Deviation of 3.31. Apyx Medical Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Apyx Medical Corp, which can be compared to its rivals. Please confirm Apyx Medical Corp jensen alpha and semi variance to decide if Apyx Medical Corp is priced correctly, providing market reflects its regular price of 6.94 per share. Given that Apyx Medical has jensen alpha of (0.89), we suggest you to validate Apyx Medical Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Apyx Medical

While some firms in the medical devices industry are either recovering or due for a correction, Apyx Medical may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 16th of March 2022, our analysis shows that Apyx Medical responds to the market. The company is undervalued and projects close to average probability of distress for the next 2 years. Our latest 90 days buy-or-sell advice on the company is Cautious Hold.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Apyx Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com